Prescribing in Pregnancy
Treatment of rheumatic diseases M A BYRON Musculoskeletal disorders are common, and conditions such as low back pain and carpal tunnel syndrome may require treatment during pregnancy. Rheumatic conditions are more common in women, with the peak prevalence of rheumatoid arthritis and systemic lupus erythematosus occurring in women of childbearing age. Antirheumatic drugs are, therefore, often required for women of childbearing age.' Table I lists the groups of drugs prescribed for rheumatic conditions. Analgesics and non-steroidal anti-inflammatory drugs are most commonly prescribed, some of which-for example, ibuprofen-are now available without prescription. Several reviews discuss the effects of these drugs during pregnancy and lactation'-' 26 and therapeutic gold concentrations have been detected in cord blood without evidence of congenital defects." BREAST FEEDING Trace amounts of aurothioglucose have been detected in the milk of lactating women, and gold has been found bound to the red blood cells of breast fed infants.3 The theoretical possibility of toxicity precludes its use during breast feeding.
Penicillamine
The chelating agent penicillamine (dimethylcysteine) is used for treating Wilson's disease, cystinuria, and rheumatoid arthritis. Its use in pregnancy has been associated with the development of a generalised connective tissue defect, similar to that of EhlersDanlos syndrome, in three babies.28130 Two died, but in the third the cutis laxa was reversible. Many normal children, however, have been born to mothers taking penicillamine for Wilson's disease, 3' 32 and it was proposed that in this disease the fetus was protected from the effects of penicillamine by the excessive maternal pool of copper. In another survey, however, one ventricular septal defect was the only abnormality reported in 27 pregnancies in patients with rheumatoid arthritis and cystinuria.33 BREAST 
FEEDING
Penicillamine is extensively protein bound and has a short half life, so only small amounts should be present in breast milk. No specific investigations in lactation have, however, been carried out. The potential toxicity makes its use hazardous.
Corticosteroids
The pharmacology of corticosteroids and potential effects on the fetus are discussed in the article on treatment of asthma. In Penicillamine two studies of pregnancy associated with corticosteroid treatment 37 pregnancies in 24 patients with rheumatic diseases were evaluated.435 Although five pregnancies resulted in abortion and four in fetal death, this was in a group of patients at high risk offetal loss. Length ofgestation and birth weight were within normal limits and a few minor fetal abnormalities were considered unrelated to steroid treatment in the mother. Both studies emphasised the importance of giving the mother additional corticosteroids during delivery and the rarity of fetal adrenocortical insufficiency. BREAST FEEDING In the doses most commonly used for treating rheumatic diseases (15 mg ofprednisolone a day or less) there is little chance ofan infant receiving appreciable amounts of prednisolone in breast milk.86
Cytotoxic drugs
Alkylating agents and antimetabolites may be teratogenic and mutagenic, and even ifused after the first trimester ofpregnancy the fetus is susceptible to bone marrow depression, infection, and haemorrhage.37 Azathioprine is the cytotoxic agent most commonly used in rheumatic disorders. In a study of 125 pregnancies in renal transplant recipients taking both azathioprine and prednisone only one infant showed a congenital abnormality, though a number had lymphopenia, growth retardation, and an increase in chromosomal breakage.?8 Results of long term follow up studies in these children are not available. The risk of lymphoproliferative and gonadal disorders would be likely to cause concern.
BREAST FEEDING Many cytotoxic drugs are found in appreciable amounts in human milk, and the risk to the infant would outweigh any benefits of breast feeding.
Guidelines for antirheumatic treatment in pregnancy
Adequate explanations of the possible risks of any proposed treatment, with appropriate advice on contraception, are essential when treating women of childbearing age. The use of drugs that pose the least threat to the fetus will minimise anxiety should pregnancy occur. In women with established rheumatic diseases it is important to appreciate that without the use of agents which suppress the disease pregnancy may not have occurred or may not have been carried to term. Adequate control of the disease may also enable a woman to feel capable of bearing and raising children. There is a good chance of remission of rheumatoid arthritis during pregnancy, though aggressive treatment may continue to be necessary in systemic lupus erythematosus.2
NON-STEROIDAL ANTI-INFLAMMATORY AGENTS
Drug action is a function ofconcentration and time. To minimise the effects on the fetus drugs with a short elimination half life and inactive metabolites-for example, ibuprofen, flurbiprofen, and ketoprofen-should be used at the maximum tolerated dosage interval. The most potent inhibitors of prostaglandin synthesis, such as salicylates and indomethacin, should be avoided throughout pregnancy, if possible, and certainly during the last trimester. Well motivated women with moderate symptoms may be managed with simple analgesics, paracetamol being the drug of choice.
DRUGS THAT MODIFY RHEUMATIC DISEASE
Only a small proportion of women require disease modifying drugs. Antimalarial drugs are contraindicated in pregnancy or lactation, whereas sulphasalazine appears to be safe, though folate supplements should be given. Treatment with gold and penicillamine should not be started during pregnancy, and these drugs should not be used by breast feeding women. If a woman becomes pregnant while taking these drugs gold can be continued at the longest possible dosage interval and penicillamine should be slowly reduced or withdrawn. Pyroxidine supplements are recommended as penicillamine may deplete maternal stores.3 Careful consideration should be given to the use of cytotoxic agents in pregnancy. Although azathioprine appears to be relatively safe, long term follow up data are not yet available. Corticosteroids in the doses required to treat rheumatic conditions seem to be safe in pregnancy and lactation. Additional doses are needed to cover delivery. Fetal adrenal insufficiency is rare.
